Wait till we see data from patients that are`nt already on deaths door,I`m sure we`ll see a big jump in survival % rate,and that`s for the LM by itself,so IMO,data in combination with Keytruda on earlier stage patients will be awesome,and Merck will need to be in on the bidding war,so as to keep ADXS out of the hands of AMGN,and BMY. Astra won`t have enough money in their kitty to be apart of the bidding war for ADXS. I`m sure the company is in talks for our EU partner and then they`ll submit the application to the EU,with the help of the partner,and once approved, ADXS will be up for grabs to highest bidder. The company knows this all too well,and they`re not gonna give the company away for peanuts when they`re so close to doing the gold rush jig. IMO,and in many others that know way more than us,the approval is going to happen,in the EU and the FDA,because ADXS has the goods,,,Ridiculously cheap cost for production,per dose,and almost zero side effects,if you count flu like symptoms as anything, compared to plenty of approved drugs out there with horrible side effects.. GLTAL.
Market Data 
Markets 
AI
